Drug makers see their returns on R&D tumble.(News)

Investment returns from researching new drugs have fallen nearly 30% in the past year at the world's 12 top pharmaceutical companies, according to a report by Deloitte LLP and Thomson Reuters. The analysis shows the average internal rate of …